Highlights
- Osteopore plans to sell its orthopaedic bone scaffolds directly in Singapore from the beginning of January 2027.
- The company will end its exclusive Singapore distribution arrangement with DKSH at the close of December 2026.
- Osteopore has added distribution agreements across Asia and the Middle East while managing a net Liability position.
- Osteopore continues to track clinical studies in Queensland involving patients receiving cleft lip treatment and jaw reconstruction.
Osteopore Limited (ASX:OSX), the Singapore-founded maker of 3D-printed bone-healing scaffolds, is taking sales of its orthopaedic products in its home market in-house. In an announcement on 2 November 2026 the company said its exclusive Singapore distribution arrangement with DKSH would end on 31 December 2026, with Osteopore selling directly from 1 January 2027. The move caps a year of new distribution deals across Asia and the Middle East, set against a Balance Sheet still in a net liability position.
What Osteopore does
Osteopore is an ASX-listed medical technology company whose products are bioresorbable scaffolds, printed in three dimensions, designed to support natural bone regeneration and then be absorbed by the body. It sells into craniofacial, neurosurgical, orthopaedic and dental applications, including custom-made implants, through distributors in a range of Asian, European, Middle Eastern and Latin American markets.
Recent developments
According to the 2 November announcement, the DKSH agreement for Singapore orthopaedic products had been announced in November 2024 as a five-year exclusive contract, and has been ended early by agreement. The company said its orthopaedic products were in use at all major Singapore public hospitals within two years and that direct selling would let it offer related products, including 3D printing services and a planned injectable bone filler, to the same customers. DKSH remains its dental partner in Malaysia. No financial impact was quantified.
Other announcements in the second half of 2026 included the completion of its first custom orthopaedic implant cases in Hong Kong and Hainan, a three-year orthopaedic distribution agreement covering five Middle East countries on 6 August, and market access in Thailand's orthopaedic sector on 9 September. Clinical studies continue at Queensland Children's Hospital in cleft lip patients and at Princess Alexandra Hospital in jaw reconstruction; these are trials, not new approvals.
Financial position
The half-year report to 30 June 2026, dated 31 August and reviewed by new auditor Pitcher Partners, showed Revenue of about AUD 1.43 million, down 8% from the prior period, which the company attributed largely to a stronger Australian dollar. Cash at 30 June was about AUD 1.25 million.
Osteopore reported a net liability position of about AUD 1.80 million, mainly because of convertible notes with about AUD 2.45 million Face Value outstanding. The notes bear 4% interest, convert at 80% of a five-day volume-weighted average price, and mature in February 2028, under a Facility of up to AUD 20 million with Advance Opportunities Fund.
The company's September quarter activities report and Appendix 4C were lodged on 30 October 2026; we were unable to review their figures.
Share Trading on 16 November
Such low turnover means the unchanged price may reflect a stale last trade.
Risks and what to watch
Osteopore's revenue base remains small relative to its cost of entering new markets, and the half-year report noted slower adoption of custom cranial implants in Europe. Its reliance on convertible notes priced at a discount to the Market Price creates ongoing dilution risk, particularly at current share price levels. Moving to direct sales in Singapore adds sales and Marketing responsibility.
Near-term milestones include the transition to direct selling on 1 January 2027, progress of the Queensland and Brisbane clinical studies, the launch of the injectable bone filler, and the December quarter Cash Flow report.
_11_16_2026_07_52_44_870464.jpg)




_11_16_2026_07_55_02_604226.jpg)
Please wait processing your request...